{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:51:35Z","timestamp":1784911895435,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20180278"],"award-info":[{"award-number":["20180278"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"crossref","award":["2018-02760"],"award-info":[{"award-number":["2018-02760"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute dyspnea with underlying congestion is a leading cause of emergency department (ED) visits with high rates of hospitalization. Adrenomedullin is a vasoactive neuropeptide hormone secreted by the endothelium that mediates vasodilation and maintains vascular integrity. Plasma levels of biologically active adrenomedullin (bio-ADM) predict septic shock and vasopressor need in critically ill patients and are associated with congestion in patients with acute heart failure (HF) but the prognostic value in unselected dyspneic patients at the ED is unknown. The purpose of this study is to test if bio-ADM predicts adverse outcomes when sampled in patients with acute dyspnea at presentation to the ED. In this single-center prospective observational study, we included 1402 patients from the ADYS (Acute DYSpnea at the Emergency Department) cohort in Malm\u00f6, Sweden. We fitted logistic regression models adjusted for sex, age, N-terminal pro-B-type natriuretic peptide (NT-proBNP), creatinine, and C-reactive protein (CRP) to associate bio-ADM plasma levels to mortality, hospitalization, intravenous (IV) diuretic treatment and HF diagnosis. Using receiver operating characteristic (ROC) curve analysis we evaluated bio-ADM discrimination for these outcomes compared to a reference model (sex, age, NT-proBNP, creatinine, and CRP). Model performance was compared by performing a likelihood ratio test on the deviances of the models. Bio-ADM (per interquartile range from median) predicts both 90-day mortality [odds ratio (OR): 1.5, 95% confidence interval (CI) 1.2\u20132.0, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.002] and hospitalization (OR: 1.5, 95% CI 1.2\u20131.8, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) independently of sex, age, NT-proBNP, creatinine, and CRP. Bio-ADM statistically significantly improves the reference model in predicting mortality (added <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup> 9.8, <jats:italic>p<\/jats:italic>\u2009=\u20090.002) and hospitalization (added <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup> 14.1, <jats:italic>p<\/jats:italic>\u2009=\u20090.0002), and is associated with IV diuretic treatment and HF diagnosis at discharge. Plasma levels of bio-ADM sampled at ED presentation in acutely dyspneic patients are independently associated with 90-day mortality, hospitalization and indicate the need for decongestive therapy.<\/jats:p>","DOI":"10.1007\/s11739-021-02776-y","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T13:02:25Z","timestamp":1624712545000},"page":"541-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bioactive adrenomedullin a prognostic biomarker in patients with mild to moderate dyspnea at the emergency department: an observational study"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-2655","authenticated-orcid":false,"given":"Kevin","family":"Bronton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-2240","authenticated-orcid":false,"given":"Torgny","family":"Wessman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas","family":"Gr\u00e4nsbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janin","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2581-484X","authenticated-orcid":false,"given":"Olle","family":"Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"issue":"49","key":"2776_CR1","first-page":"834","volume":"113","author":"D Berliner","year":"2016","unstructured":"Berliner D, Schneider N, Welte T, Bauersachs J (2016) The Differential Diagnosis of Dyspnea. Dtsch Arztebl Int. 113(49):834\u2013845","journal-title":"Dtsch Arztebl Int."},{"issue":"2","key":"2776_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ejhf.1366","volume":"21","author":"AA Voors","year":"2019","unstructured":"Voors AA, Kremer D, Geven C, ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, D\u00fcngen H-D et al (2019) Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail 21(2):163\u2013171","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2776_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1006\/bbrc.1993.1451","volume":"192","author":"K Kitamura","year":"1993","unstructured":"Kitamura K, Kangawa K, Kawamoto M, Ichiki YNS, Matsuo H, Eto T (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192(2):553\u2013560","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2776_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1006\/bbrc.1994.1827","volume":"201","author":"S Shin","year":"1994","unstructured":"Shin S, Naoto M, Kenji K, Kaoru M, Kazuo K, Junichiro S, Tanenao E, Hisayuki M (1994) Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 201(3):1160\u20131166","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2776_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1006\/bbrc.1998.8310","volume":"244","author":"K Kazuo","year":"1998","unstructured":"Kazuo K, Johji K, Mari K, Miho T, Naoyoshi C, Kenji K, Tanenao E (1998) The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma. Biochem Biophys Res Commun 244(2):551\u2013555","journal-title":"Biochem Biophys Res Commun"},{"key":"2776_CR6","doi-asserted-by":"crossref","unstructured":"Cuttitta F, Mart\u00ednez A (2013) Adrenomedullin. In: Kastin A (ed) Handbook of Biologically Active Peptides, 2nd edn. Academic Press, Elsevier, pp 489\u2013493","DOI":"10.1016\/B978-0-12-385095-9.00066-X"},{"issue":"19","key":"2776_CR7","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.jacc.2010.02.025","volume":"55","author":"A Maisel","year":"2010","unstructured":"Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M et al (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55(19):2062\u20132076","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2776_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1373\/jalm.2017.023655","volume":"2","author":"J Weber","year":"2017","unstructured":"Weber J, Sachse J, Bergmann S, Sparwa\u00dfer A, Struck J, Bergmann A (2017) Sandwich immunoassay for bioactive plasma adrenomedullin. J App Lab Med 2(2):222\u2013233","journal-title":"J App Lab Med"},{"issue":"2","key":"2776_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.chest.2017.03.035","volume":"152","author":"P Caironi","year":"2017","unstructured":"Caironi P, Latini R, Struck J, Hartmann O, Bergmann A, Maggio G, Cavana M, Tognoni G, Pesenti A, Gattinoni L et al (2017) Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis. Chest 152(2):312\u2013320","journal-title":"Chest"},{"key":"2776_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2243-2","author":"A Mebazaa","year":"2018","unstructured":"Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman BG, Blet A, Gayat E, Hartmann O, Scigalla P, Struck J et al (2018) Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational adrenomedullin and outcome in sepsis and septic shock-1 (AdrenOSS-1) study. Crit Care. https:\/\/doi.org\/10.1186\/s13054-018-2243-2","journal-title":"Crit Care"},{"key":"2776_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fimmu.2018.00292","volume":"9","author":"C Geven","year":"2018","unstructured":"Geven C, Kox M, Pickkers P (2018) Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis. Front Immunol 9:292","journal-title":"Front Immunol"},{"issue":"5","key":"2776_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3343\/alm.2019.39.5.454","volume":"39","author":"H Kim","year":"2019","unstructured":"Kim H, Hur M, Struck J, Bergmann A, Di Somma S (2019) Circulating biologically active adrenomedullin predicts organ failure and mortality in sepsis. Ann Lab Med 39(5):454\u2013463","journal-title":"Ann Lab Med"},{"key":"2776_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcrc.2016.10.017","volume":"38","author":"TP Simon","year":"2017","unstructured":"Simon TP, Martin L, Doemming S, Humbs A, Bruells C, Kopp R, Hartmann O, Struck J, Bergmann A, Marx G et al (2017) Plasma adrenomedullin in critically ill patients with sepsis after major surgery: a pilot study. J Crit Care 38:68\u201372","journal-title":"J Crit Care"},{"issue":"1","key":"2776_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13054-020-2794-x","volume":"24","author":"A Blet","year":"2020","unstructured":"Blet A, de Roquetaillade C, Hartmann O, Struck J, Mebazaa A, Chousterman BG (2020) Adrenoss-1 study i: added value of serial bio-adrenomedullin measurement in addition to lactate for the prognosis of septic patients admitted to ICU. Crit Care 24(1):69","journal-title":"Crit Care"},{"issue":"1","key":"2776_CR15","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/cc13731","volume":"18","author":"R Marino","year":"2014","unstructured":"Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S (2014) Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care 18(1):R34","journal-title":"Crit Care"},{"issue":"1","key":"2776_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13613-016-0229-2","volume":"7","author":"H Tolppanen","year":"2017","unstructured":"Tolppanen H, Rivas-Lasarte M, Lassus J, Sans-Rosello J, Hartmann O, Lindholm M, Arrigo M, Tarvasmaki T, Kober L, Thiele H et al (2017) Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock. Ann Intensive Care 7(1):6","journal-title":"Ann Intensive Care"},{"issue":"2","key":"2776_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ajem.2015.10.033","volume":"34","author":"WH Self","year":"2016","unstructured":"Self WH, Storrow AB, Hartmann O, Barrett TW, Fermann GJ, Maisel AS, Struck J, Bergmann A, Collins SP (2016) Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure. Am J Emerg Med 34(2):257\u2013262","journal-title":"Am J Emerg Med"},{"issue":"2","key":"2776_CR18","doi-asserted-by":"publisher","first-page":"e001048","DOI":"10.1136\/openhrt-2019-001048","volume":"6","author":"J Molvin","year":"2019","unstructured":"Molvin J, Jujic A, Navarin S, Melander O, Zoccoli G, Hartmann O, Bergmann A, Struck J, Bachus E, Di Somma S et al (2019) Bioactive adrenomedullin, proenkephalin A and clinical outcomes in an acute heart failure setting. Open Heart 6(2):e001048","journal-title":"Open Heart"},{"issue":"6","key":"2776_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ejhf.1437","volume":"21","author":"JM Ter Maaten","year":"2019","unstructured":"Ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, Ng LL, Dickstein K, Metra M, Samani NJ et al (2019) Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail 21(6):732\u2013743","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2776_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/ejhf.1245","volume":"20","author":"D Kremer","year":"2018","unstructured":"Kremer D, Ter Maaten JM, Voors AA (2018) Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure. Eur J Heart Fail 20(9):1363\u20131365","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2776_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ejhf.1693","volume":"22","author":"P Pandhi","year":"2020","unstructured":"Pandhi P, Ter Maaten JM, Emmens JE, Struck J, Bergmann A, Cleland JG, Givertz MM, Metra M, O\u2019Connor CM, Teerlink JR et al (2020) Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. Eur J Heart Fail 22(4):683\u2013691","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2776_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/SHK.0000000000000473","volume":"45","author":"C Ince","year":"2016","unstructured":"Ince C, Mayeux PR, Nguyen T, Gomez H, Kellum JA, Ospina-Tasc\u00f3n GA, Hernandez G, Murray P, De Backer D (2016) The endothelium in sepsis. Shock 45(3):259\u2013270","journal-title":"Shock"},{"issue":"6","key":"2776_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/bjaceaccp\/mkv003","volume":"15","author":"JR Greer","year":"2015","unstructured":"Greer JR (2015) Pathophysiology of cardiovascular dysfunction in sepsis. BJA Educ 15(6):316\u2013321","journal-title":"BJA Educ"},{"issue":"27","key":"2776_CR24","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129\u20132200","journal-title":"Eur Heart J"},{"issue":"1","key":"2776_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ (1950) Index for rating diagnostic tests. Cancer 3(1):32\u201335","journal-title":"Cancer"},{"issue":"9","key":"2776_CR26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/sim.5727","volume":"32","author":"MS Pepe","year":"2013","unstructured":"Pepe MS, Kerr KF, Longton G, Wang Z (2013) Testing for improvement in prediction model performance. Stat Med 32(9):1467\u20131482","journal-title":"Stat Med"},{"key":"2776_CR27","first-page":"174","volume":"22","author":"M Arrigo","year":"2019","unstructured":"Arrigo M, Parenica J, Ganovska E, Pavlusova M, Mebazaa A (2019) Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome. Int J Cardiol Heart Vasc 22:174\u2013176","journal-title":"Int J Cardiol Heart Vasc"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-021-02776-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-021-02776-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-021-02776-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T10:25:50Z","timestamp":1648549550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-021-02776-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2776"],"URL":"https:\/\/doi.org\/10.1007\/s11739-021-02776-y","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"11 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SphingoTec GmbH is the manufacturer of the bio-ADM assay and facilitated transport and analysis of bio-ADM and NT-proBNP in the study samples. Schulte and Hartman are employees of Sphingotec GmbH. Melander is listed as an inventor on a patent application owned by SphingoTec GmbH regarding the use of bio-ADM in the prediction and diagnosis of dementia. The remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the declaration of Helsinki. Approval was granted by the Regional Ethical Review Board in Lund (Dnr 2012\/762).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"We obtained both written and oral consent from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}